155 related articles for article (PubMed ID: 36584630)
1. Design and synthesis of improved active-site SHP2 inhibitors with anti-breast cancer cell effects.
Lade DM; Nicoletti R; Mersch J; Agazie YM
Eur J Med Chem; 2023 Feb; 247():115017. PubMed ID: 36584630
[TBL] [Abstract][Full Text] [Related]
2. Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine Phosphatase SHP2 with Anti-Breast Cancer Cell Effects.
Hartman Z; Geldenhuys WJ; Agazie YM
ACS Omega; 2020 Oct; 5(39):25113-25124. PubMed ID: 33043190
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment.
Luo R; Fu W; Shao J; Ma L; Shuai S; Xu Y; Jiang Z; Ye Z; Zheng L; Zheng L; Yu J; Zhang Y; Yin L; Tu L; Lv X; Li J; Liang G; Chen L
Eur J Med Chem; 2023 May; 253():115305. PubMed ID: 37023678
[TBL] [Abstract][Full Text] [Related]
4. Benzo[c][1,2,5]thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
Wang WL; Chen XY; Gao Y; Gao LX; Sheng L; Zhu J; Xu L; Ding ZZ; Zhang C; Li JY; Li J; Zhou YB
Bioorg Med Chem Lett; 2017 Dec; 27(23):5154-5157. PubMed ID: 29100798
[TBL] [Abstract][Full Text] [Related]
5. Targeting SHP2 with an Active Site Inhibitor Blocks Signaling and Breast Cancer Cell Phenotypes.
Lade DM; Agazie YM
ACS Bio Med Chem Au; 2023 Oct; 3(5):418-428. PubMed ID: 37876496
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors.
Meng XD; Gao LX; Wang ZJ; Feng B; Zhang C; Satheeshkumar R; Li J; Zhu YL; Zhou YB; Wang WL
Bioorg Chem; 2021 Nov; 116():105384. PubMed ID: 34601294
[TBL] [Abstract][Full Text] [Related]
7. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).
Hartman Z; Geldenhuys WJ; Agazie YM
J Biol Chem; 2020 Mar; 295(11):3563-3575. PubMed ID: 32024694
[TBL] [Abstract][Full Text] [Related]
8. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
9. A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors.
Song Y; Zhao M; Wu Y; Yu B; Liu HM
Acta Pharm Sin B; 2021 Mar; 11(3):750-762. PubMed ID: 33777680
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors.
Tang K; Zhao M; Wu YH; Wu Q; Wang S; Dong Y; Yu B; Song Y; Liu HM
Eur J Med Chem; 2022 Feb; 230():114106. PubMed ID: 35063735
[TBL] [Abstract][Full Text] [Related]
11. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
12. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of heterocyclic bis-aryl amides as novel Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
Satheeshkumar R; Zhu R; Feng B; Huang C; Gao Y; Gao LX; Shen C; Hou TJ; Xu L; Li J; Zhu YL; Zhou YB; Wang WL
Bioorg Med Chem Lett; 2020 Jun; 30(11):127170. PubMed ID: 32273218
[TBL] [Abstract][Full Text] [Related]
15. Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2).
Day JEH; Berdini V; Castro J; Chessari G; Davies TG; Day PJ; St Denis JD; Fujiwara H; Fukaya S; Hamlett CCF; Hearn K; Hiscock SD; Holvey RS; Ito S; Kandola N; Kodama Y; Liebeschuetz JW; Martins V; Matsuo K; Mortenson PN; Muench S; Nakatsuru Y; Ochiiwa H; Palmer N; Peakman T; Price A; Reader M; Rees DC; Rich SJ; Shah A; Shibata Y; Smyth T; Twigg DG; Wallis NG; Williams G; Wilsher NE; Woodhead A; Shimamura T; Johnson CN
J Med Chem; 2024 Mar; 67(6):4655-4675. PubMed ID: 38462716
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2.
Kostrzewa T; Sahu KK; Gorska-Ponikowska M; Tuszynski JA; Kuban-Jankowska A
Drug Des Devel Ther; 2018; 12():4139-4147. PubMed ID: 30584278
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors.
Liu WS; Yang B; Wang RR; Li WY; Ma YC; Zhou L; Du S; Ma Y; Wang RL
Bioorg Chem; 2020 Jul; 100():103875. PubMed ID: 32380342
[TBL] [Abstract][Full Text] [Related]
18. Identification of demethylincisterol A
Chen C; Liang F; Chen B; Sun Z; Xue T; Yang R; Luo D
Eur J Pharmacol; 2017 Jan; 795():124-133. PubMed ID: 27939989
[TBL] [Abstract][Full Text] [Related]
19. Toward a Treatment of Cancer: Design and In Vitro/In Vivo Evaluation of Uncharged Pyrazoline Derivatives as a Series of Novel SHP2 Inhibitors.
Dai J; Zhang Y; Gao Y; Bai X; Liu F; Li S; Yu Y; Hu W; Shi T; Shi D; Li X
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408869
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of SHP2 as an approach to block RAS-driven cancers.
Chou YT; Bivona TG
Adv Cancer Res; 2022; 153():205-236. PubMed ID: 35101231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]